SEARCH

SEARCH BY CITATION

References

  • 1
    Hepatitis B fact sheet number 204. Geneva: World Health Organization, October 2000. Available at: http://www.who.int/mediacentre/factsheets/fs204/en. Accessed March 10, 2005.
  • 2
    Liaw YF, Leung N, Guan R, Lau GKK, Merican I, McCaughan G, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25: 472489.
  • 3
    Lok A, McMahon BJ. AASLD chronic hepatitis B: update of recommendations. HEPATOLOGY 2004; 39: 857861.
  • 4
    Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann H-W L, Goodman Z, et al. Lamivudine as an initial treatment for chronic hepatitis B in the United States. N Eng J Med 1999; 341: 12561263.
  • 5
    Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. N Eng J Med 1998; 339: 6168.
  • 6
    Liaw YF, Sung JY, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Eng J Med 2004; 351: 15211531.
  • 7
    Guan R, Lai CL, Liaw YF, Lim SG, Lee CM. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2001; 16( S): A60.
  • 8
    Dienstag J, Goldin R, Heathcote E, Hann H-W, Woessner M, Stephenson S, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105117.
  • 9
    Lai CL, Dienstag J, Schiff E, Leung N, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD mutants during lamivudine therapy of patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687696.
  • 10
    Intron A. Kenilworth, NJ: Schering, 2001 (package insert).
  • 11
    Marcellin P, Chang T T, Lim S G, Tong M, Sievert W, Shiffman M, et al. Adefovir dipivoxil for the treatment of Hepatitis B e antigen–positive chronic hepatitis B. N Engl J Med 2003; 348: 808816.
  • 12
    Hadziyannis S, Tassopoulos N, Heathcote E, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen–negative chronic hepatitis B. N Engl J Med 2003; 348: 800807.
  • 13
    Marcellin P, Chang TT, Lim S, Sievert W, Tong M, Arterburn S, et al. Increasing serologic, virologic and biochemical response over time to adefovir dipivoxil (ADV) 10 mg in HBeAg-positive chronic hepatitis B (CHB) patients. J Hepatol 2005; 42( Suppl 2): 31.
  • 14
    Hadziyannis SJ, Tassopoulos N, Chang TT, Heathcote J, Kitis G, Rizzetto M, et al. Adefovir dipivoxil (ADV) demonstrates sustained efficacy in HBeAg- chronic hepatitis B (CHB) patients. J Hepatol 2005; 42( Suppl 2): 178.
  • 15
    Schiff E, Lai CL, Neuhaus P, Tillman H, Samuel D, Villeneuve JP, et al. Long-term safety and efficacy of adefovir dipivoxil (ADV) in the treatment of chronic hepatitis B in patients pre- and post-liver transplantation (OLT) with lamivudine resistant (Lam-R) hepatitis B virus (HBV) [Abstract]. HEPATOLOGY 2004; 40( Suppl 1): 660A.
  • 16
    Xiong X, Flores C, Yang H, Toole J, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. HEPATOLOGY 1998; 28: 16691673.
  • 17
    Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. HEPATOLOGY 2000; 32: 129134.
  • 18
    Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet M, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open label pilot study. Lancet 2001; 358: 718723.
  • 19
    Westland C, Yang H, Delaney W, Gibbs C, Miller M, Wulfsohn M, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. HEPATOLOGY 2003; 38: 96103.
  • 20
    Xiong S, Yang H, Westland C, Delaney W, Colledge D, Bartholomeusz A, et al. Resistance surveillance of HBeAg- chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV). J Hepatol 2003; 38( Suppl 2): 182.
  • 21
    Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292297.
  • 22
    Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart C, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplant patient. J Hepatol 2003; 89: 10851089.
  • 23
    Locarnini S, Qi W, Arterburn S, Snow A, Brosgart CL, Currie G, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patents with chronic hepatitis B (CHB). J Hepatol 2005; 42( Suppl 2): 17.
  • 24
    Ware JE, Gandeck B. Overview of the SF-36 health survey and the International Quality of Life Assessment (IQOL) project. J Clin Epidemiol 1998; 51: 903912.
  • 25
    Heathcote J, Chang TT, Lim SG, Hadziyannis S, Tassopoulos N, Tong M, et al. Safety profile of 48 weeks of adefovir dipivoxil 10 mg for the treatment of chronic hepatitis B: an integrated analysis of two Phase III studies [Abstract 1882]. HEPATOLOGY 2002; 36: 633A.
  • 26
    Chang TT, Lim SG, Hadziyannis S, Tassopoulos N, Tong M, Sievert W, et al. Long term safety of adefovir dipivoxil (10 mg) once daily for chronic hepatitis B: an integrated analysis of two phase III studies [Abstract 454]. J Hepatol 2003; 38( Suppl 2); 133.
  • 27
    Hadziyannis SJ, Tassopoulos N, Heathcote J, Chang TT, Kitis G, Rizzetto M, et al. Long term therapy with adefovir dipivoxil for HBeAg negative chronic hepatitis B. N Eng J Med 2005; 352: 26732681
  • 28
    Tassopoulus NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, et al. Efficacy of lamivudine in subjects with Hepatitis B e antigen-negative/hepatitis B virus DNA-positive (pre-core mutant) chronic hepatitis B. HEPATOLOGY 1999; 29: 889896.
  • 29
    Peters MG, Hann HW, Martin P, Heathcote EJ, Buggish P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91100.
  • 30
    Benhamou Y, Bochet M, Thibalt V, Heathcote EJ, Buggish P, Rubin R, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358: 718723.